A genome-wide association study of acenocoumarol maintenance dosage

Human Molecular Genetics

Volumn 18, Issue 19, 2009, Pages 3758-3768

  Teichert, Martina ^a,b   Eijgelsheim, Mark ^a   Rivadeneira, Fernando ^a   Uitterlinden, Andre G ^a,b   van Schaik, Ron H N ^a,d   Hofman, Albert ^a,c   De Smet, Peter A G M ^b,e   van Gelder, Teun ^a   Visser, Loes E ^a   Stricker, Bruno H Ch ^a,c,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Scientific Institute Dutch Pharmacists   (Netherlands)

^c Netherlands Genomics Initiative   (Netherlands)

^d STAR Medical Diagnostic Center   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Drug Safety Unit   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

AGED; ARTICLE; DOSE RESPONSE; DRUG THERAPY; FEMALE; GENETIC ASSOCIATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 70350754462     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp309     Document Type: Article

References (34)

1. Montes, R., Ruiz de Gaona, E., Martinez-Gonzalez, M.A., Alberca, I. and Hermida, J. (2006) The c.-1639G>A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br. J. Haematol., 133, 183-187.
2. Schalekamp, T., Brassé, B.P., Roijers, J.F.M., Chahid, Y., van Geest-Daalderop, J.H.H., de Vries-Goldschmeding, H., van Wijk, E.M., Egberts, A.C.G. and de Boer, A. (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther., 80, 13-22.
3. Aquilante, C.L., Langaee, T.Y., Lopez, L.M., Yarandi, H.N., Tromberg, J.S., Mohuczy, D., Gaston, K.L., Waddell, C.D., Chirico, M.J. and Johnson, J.A. (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharm. Therap., 79, 291-302.
4. Carlquist, J.F., Home, B.D., Muhlestein, J.B., Lappé, D.L., Whiting, B.M., Kolek, M.J., Clarke, J.L., James, B.C. and Anderson, J.L. (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis, 22, 191-197.
5. Crawford, D.C., Ritchie, M.D. and Rieder, M.J. (2007) Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics, 8, 487-496.
6. D'Andrea, G., D'Ambrosio, R.L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105, 645-649.
7. Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E., Muller, C.R., Wienker, T.F. and Oldenburg, J. (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost., 94, 773-779.
8. Oldenburg, J., Bevans, C.G., Fregin, A., Geisen, C., Müller-Reible, C. and Watzka, M. (2007) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb. Haemost., 98, 570-578.
9. Reitsma, P.H., van der Heijden, J.F., Groot, A.P., Rosendaal, F.R. and Buller, H.R. (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med., 2, e312.
10. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. and Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329-2333.
11. Li, C., Schwarz, U.I., Ritchie, M.D., Roden, D.M., Stein, C.M. and Kurnik, D. (2008) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 113, 3925-3930.
12. Wadelius, M., Chen, L.Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R. and Deloukas, P. (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet., 121, 23-34.
13. Caldwell, M.D., Awad, T., Johnson, J.A., Gage, B.F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T.Y., Eby, C. et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood, 111, 4106-4112.
14. Borgiani, P., Ciccacci, C., Forte, V., Sirianni, E., Novelli, L., Bramanti, P. and Novelli, G. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics, 10, 261-266.
15. Food Drug Administration F (2007) FDA approves updated warfarin (Coumadin) prescribing information. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2002/ncm108961.html Accessed 24 June 2008.
16. College voor Zorgverzekeringen (2009) GIP databank. http://www.gipdatabank.nl/ visited 4th of march 2009.
17. Bodin, L., Verstuyft, C., Tregouet, D.A., Robert, A., Dubert, L., Funck-Brentano, C., Jaillon, P., Beaune, P., Laurent-Puig, P., Becquemont, L. et al. (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 106, 135-140.
18. Spreafico, M., Lodigiani, C., van Leeuwen, Y., Pizzotti, D., Rota, L.L., Rosendaal, F.R., Mannucci, P.M. and Peyvandi, F. (2008) Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Fut. Med., 9, 1237-1250.
19. Teichert, M., van Schaik, R.H.N., Hofman, A., Uitterlinden, A.G., de Smet, P., Stricker, B. and Visser, L.E. (2009) Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin. Pharmacol. Ther., 85, 379-386.
20. Markatos, C.N., Grouzi, E., Politou, M., Gialeraki, A., Merkouri, E., Panagou, I., Spiliotopoulou, I. and Travlou, A. (2008) VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics, 9, 1631-1638.
21. Verde, Z., Santiago, C., Valle, B., Fernández-Santander, A., Bandrés, F., Calvo, E., Ruiz, J., Lucía, A. and Gallego, F. (2009) Pharmacogenetics of acenocoumarol: CYP2C9*2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. Thromb. Haemost., 101, 591-593.
22. Anderson, J.L., Horne, B.D., Stevens, S.M., Grove, A.S., Barton, S., Nicholas, Z.P., Kahn, S.F.S., May, H.T., Samuelson, K.M., Muhlestein, J.B. et al. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 116, 2563-2570.
23. Caraco, Y., Blotnick, S. and Muszkat, M. (2007) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther., 83, 460-470.
24. Ufer, M. (2005) Comparative pharmacokinetics of vitamin K antagonists. Clin. Pharmacokinet., 44, 1227-1246.
25. Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., McLeod, H.L., Blough, D.K., Thummel, K.E., Veenstra, D.L. and Rettie, A.E. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med., 352, 2285-2293.
26. Cooper, G.M., Johnson, J.A., Langaee, T.Y., Feng, H., Stanaway, I.B., Schwarz, U.I., Ritchie, M.D., Stein, C.M., Roden, D.M., Smith, J.D. et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, 112, 1022-1027.
27. Sontag, T. and Parker, R.S. (2002) Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status'. J. Biol. Chem., 277, 25290-25296.
28. Hofman, A., Grobbee, D.E., de Jong, P.T. and van den Ouweland, F.A. (1991) Determinants of disease and disability in the elderly: the Rotterdam elderly study. Eur. J. Epidemiol., 7, 403-422.
29. Hofman, A., Breteler, M.M., van Duijn, C.M., Krestin, G.P., Pols, H.A., Stricker, B.H., Tiemeier, H., Uitterlinden, A.G., Vingerling, J.R. and Witteman, J.C. (2007) The Rotterdam Study: objectives and design update. Eur. J. Epidemiol., 22, 819-829.
30. Miller, S. and Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16, 1215.
31. Visser, L.E., van Vliet, M., van Schaik, R.H.N., Kasbergen, A.A.H., de Smet, P.A., Vulto, A.G., Hofman, A., van Duijn, C. and Stricker, B.H.C. (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 14, 27-33.
32. Stolk, L., van Meurs, J.B.J., Arp, P.P., Hofman, A., Pols, H.A.P. and Uitterlinden, A.G. (2008) The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk: The Rotterdam study. Bone, 42, 286-293.
33. Thijssen, H.H., Flinois, J.-P. and Beaune, P.H. (2000) Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug. Metabol. Dispos., 28, 1284-1290.
34. Pe'er, I., Yelensky, R., Altshuler, D. and Daly, M. (2008) Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Gen. Epidemiol., 32, 381-385.